INTRODUCTION
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-20% of breast carcinomas and confers an aggressive phenotype and a poor patient outcome. 1 However, the introduction of HER2-targeted therapies has dramatically changed the prognosis of these patients. 2 The addition of trastuzumab, a humanized monoclonal antibody that binds to the HER2 receptor, to chemotherapy, significantly improved both the survival of patients with metastatic and early stage, HER2-positive breast cancer. [3] [4] [5] [6] [7] [8] [9] Despite the improvement in both disease-free survival (DFS) and overall survival (OS) associated with the addition of trastuzumab to chemotherapy in early stage, HER2-positive breast disease, long-term follow-up data indicate that approximately 15% to 24% of patients still develop recurrent disease. 7, 8 Most of the research has focused on the development and addition of novel anti-HER2 drugs with optimized or different mechanisms of action to standard treatment to prevent or overcome resistance. US Food and Drug Administration (FDA)-approved drugs and their targets are summarized in Figure 1 and, beyond trastuzumab, include the monoclonal antibody pertuzumab; the antibody-drug conjugate trastuzumab-emtansine (T-DM1); the selective, reversible HER2/ epidermal growth factor receptor kinase inhibitor lapatinib; and the irreversible pan-HER2 inhibitor neratinib. An improved understanding of tumor biology indicates that HER2-positive breast cancer is a heterogeneous disease. 10, 11 This biologic heterogeneity within HER2-positive tumors can lead to different treatment sensitivities and survival outcomes. An effort also is underway to optimize and de-escalate treatment and to identify biomarkers of response or resistance, with the objective of avoiding unnecessary treatments and their related toxicities in select patients. Here, we review the background and latest evidence for the current treatment of early stage, HER2-positive breast cancer and discuss novel approaches for its management.
Cancer TRASTUZUMAB, A LANDMARK IN THE TREATMENT OF HER2-POSITIVE DISEASE The addition of trastuzumab to standard chemotherapy reduces the risk of recurrence by approximately 40% and the risk for death up to 34%, as confirmed in the pivotal adjuvant trials [3] [4] [5] and in a meta-analysis 6 that included nearly 12,000 HER2-positive patients. The benefits of trastuzumab are independent of age, tumor size, lymph node status, or hormone receptor (HR) status. 7, 8 Moreover, updated results from the pivotal adjuvant trials with 8 and 10 years of median follow-up were reassuring, not only in terms of efficacy but also in terms of cardiac safety with 1 year of adjuvant trastuzumab. [7] [8] [9] Remarkably, the Herceptin Adjuvant (HERA) trial demonstrated a significant improvement in both DFS and OS, despite a high crossover rate of 52%. 8 
Is There an Optimal Way to Combine Trastuzumab With Chemotherapy?
Most of the pivotal adjuvant trials used anthracyclinebased chemotherapy. In the recently reported update of the National Surgical Adjuvant Breast and Bowel Project Figure 1 . Targets of US Food and Drug Administration (FDA)-approved antihuman epidermal growth factor receptor 2 (anti-HER2) drugs for HER2-positive breast cancer treatment are illustrated. There are 4 members of the HER family: epidermal growth factor receptor (EGFR), HER2, HER3, and HER4. Each receptor has 3 functional domains: the extracellular-binding domain, the α-helical transmembrane segment, and the intracellular protein tyrosine kinase domain. The extracellular region is made up of 4 subdomains. Trastuzumab and ado-trastuzumab emtansine (T-DM1) bind to domain IV, and pertuzumab binds to domain II of HER2. Lapatinib is a dual inhibitor of EGFR and HER2 tyrosine kinases domains, whereas neratinib is an irreversible EGFR, HER2, and HER4 inhibitor. Akt indicates AKT serine/threonine kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK kinase; PI3K, phosphoinositide 3-kinase; Raf, proto-oncogene serine/threonine-protein kinase; Ras, rat sarcoma; SOS, son of sevenless; P, phosphorylated.
Cancer B-31 trial, at a median follow-up of 8.8 years, the addition of trastuzumab to adjuvant anthracycline-based andtaxane-based chemotherapy did not result in long-term worsening of cardiac function, cardiac symptoms, or health-related quality of life in patients without underlying cardiac disease at baseline. 12 However, 5-10% of patients in the B-31 trial and the North Central Cancer Treatment Group N9831 trial could not start adjuvant trastuzumab because of a decline in left ventricular ejection fraction that occurred after completion of anthracyclines. 4, 7 Breast Cancer International Research Group 006 study 5 is the only adjuvant trial to examine a nonanthracycline-based treatment. In that trial, patients with HER2-positive breast cancer were randomized to receive doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with or without trastuzumab or docetaxel, carboplatin, and trastuzumab (TCH). After 10.3 years of follow-up, there were numerically fewer events in the anthracycline arm, although the study was not powered to compare doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) to TCH. 9 Regarding toxicity, there were numerically more patients with cardiac toxicity (2% vs 0.4%) and treatment-related leukemia in the AC-TH arm. It is important to consider cardiac risk factors when determining the appropriate chemotherapy backbone to administer with trastuzumab and to monitor cardiac function during therapy. Factors that have been associated with increased cardiac risk include age >65 years, hypertension, obesity, pre-existing cardiac dysfunction, and lower baseline left ventricular ejection fraction. 13 Although trastuzumab added sequentially after chemotherapy has demonstrated activity, 3, 4 results from the North Central Cancer Treatment Group N9831 study 14 (which is the only trial that was designed to compare concurrent versus sequential administration of trastuzumab with a taxane) and a meta-analysis 6 suggest a trend toward better outcomes when patients receive trastuzumab concurrently with taxanes, after doxorubicin and cyclophosphamide.
Optimal Duration of Anti-HER2 Treatment
Although the original decision to give patients trastuzumab for 1 year in pivotal adjuvant trials was chosen arbitrarily, to date, the 12-month duration remains the standard of care. In the FinHER trial, women with HER2-positive breast cancer were randomly assigned to receive a 9-week course of concurrent trastuzumab with vinorelbine or docetaxel. The 3-year recurrence-free survival was significantly improved for trastuzumabtreated patients, with a trend toward improved OS; however, with longer follow-up, distant DFS was no longer statistically significant. 15 The PHARE study is a phase 3 noninferiority study that aimed to evaluate 6 versus 12 months of adjuvant trastuzumab. 16 With a median follow-up of 3.5 years, noninferiority of 6 months was not demonstrated. The Hellenic Oncology Research Group study, in which patients were randomized to receive either 12 or 6 months of trastuzumab, also failed to demonstrate noninferiority for the 6-month arm. Results from another phase 3 trial, the Short-HER study, were recently reported. 17 That study aimed to test the noninferiority of 9 weeks versus 1 year of adjuvant trastuzumab; however, the 5-year DFS did not achieve noninferiority either. 17 Efficacy results from other phase 3 studies investigating shorter durations of trastuzumab treatments are still pending, like the Persephone study. 18 Conversely, one of the questions addressed by the HERA trial 3 was whether 2 years of trastuzumab is better than 1. That trial randomized more than 5000 patients (the largest to date) with early stage, HER2-positive breast cancer who had already completed adjuvant chemotherapy to either observation or adjuvant trastuzumab for 1 or 2 years. At a median follow-up of 11 years, 2 years of trastuzumab had no additional benefit, regardless of HR status. 8 It is noteworthy that higher rates of cardiac toxicity were reported in the 2-year trastuzumab arm compared with the 1-year arm (7.3% vs 4.4%, respectively). The role of two different adjuvant HER2-targeted therapies in a sequential order for 2 years is discussed below (see neratinib). 19 
Neoadjuvant Setting
Preoperative therapy is a well established approach for the treatment of locally advanced or inflammatory breast cancer. It improves the surgical options for many patients, with the same survival benefit as postoperative treatment. In the context of operable disease however, most patients with HER2-positive tumors that measure >2 cm or lymph node-positive disease (irrespective of tumor size) receive neoadjuvant systemic therapy. The addition of trastuzumab to primary chemotherapy dramatically enhanced the achievement of a pathologic complete response (pCR). [20] [21] [22] [23] [24] [25] [26] [27] Results from neoadjuvant, randomized, phase 3 trials with chemotherapy and trastuzumab are summarized in Table 1 . 20, 22, [24] [25] [26] The achievement of a pCR is a surrogate marker of improved long-term outcome, particularly in HER2-positive disease. [20] [21] [22] 27 A large pooled analysis 21 of 12 international trials, including 11,955 patients, confirmed the prognostic value of pCR; however, that study failed to establish an association of the magnitude of difference
Cancer in pCR rates between treatment arms and differences in long-term outcome. That said, regulatory agencies have considered accelerated new drug approval in early breast cancer based on a pCR in the breast and lymph nodes. 28 Neoadjuvant treatment has become one of the most suitable scenarios to develop novel targeted therapies. It enables a rapid evaluation of primary endpoints like pCR, and smaller samples sizes are required compared with those required in the adjuvant setting. Thus, the efficacy and toxicity of novel anti-HER2 therapies and their combination as dual-blockade, as well as a subcutaneous formulation of trastuzumab and biosimilars, have been evaluated in this setting. The neoadjuvant approach also provides a significant source of tumor tissue to identify molecular heterogeneity and potential predictive biomarkers of response and resistance.
Pertuzumab
Pertuzumab is an antibody that binds HER2 in domain II (a different domain than trastuzumab), preventing homodimer and heterodimer formations (Fig. 1) . The drug blocks one of the most powerful heterodimers, HER2/ HER3, which activates several intracellular signaling cascades, including cell proliferation and survival. The addition of pertuzumab to a taxane and trastuzumab as first-line treatment in advanced, HER2-positive breast cancer improved OS by almost 16 months. 29 The activity of pertuzumab also has been studied in the neoadjuvant setting in several phase 2 trials (Table 2) .
30-33
The NeoSphere trial 30 demonstrated that dual-blockade with pertuzumab and trastuzumab plus chemotherapy produced a significantly improved pCR rate in the breast compared with chemotherapy and trastuzumab alone (46% vs 29%, respectively). It is noteworthy that the combination had a relatively safe toxicity profile and did not result in additional cardiotoxicity. In the 5-year update of that study, the addition of pertuzumab to trastuzumab and docetaxel seemed to improve progression-free survival and DFS compared with trastuzumab plus docetaxel, 34 although those analyses were not powered for formal statistical hypothesis testing. In the TRYPHAENA trial, 31 although the primary endpoint was cardiac safety of 3 pertuzumab-trastuzumabbased regimens, pCR rates (secondary endpoint) of all 3 arms were high. On the basis of those findings, the FDA granted accelerated approval of pertuzumab in the preoperative setting in 2013. It was the first FDA approval of neoadjuvant therapy for breast cancer.
Recently, the West-German Study Group ADAPT trial 32 evaluated the efficacy of 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab with or without weekly paclitaxel in the HER2-positive/HRnegative subgroup. That study, with a focus on early responders, demonstrated an impressive pCR rate of 90.5% in the dual blockade plus paclitaxel arm. 32 This pCR rate is the highest ever reported and compares favorably with the rates reported is studies with longer and more aggressive chemotherapy regimens. The BERENICE study 33 evaluated 2 anthracycline-containing chemotherapy regimens followed by paclitaxel or docetaxel with pertuzumab and trastuzumab in the neoadjuvant setting. The cardiac safety profile observed and high pCR rates achieved in both cohorts supported the use of pertuzumab and trastuzumab with a taxane after doxorubicin-based or epirubicin-based chemotherapy in this scenario. Most patients in the study had HER2-enriched tumors, and the highest pCR rate (75%) was observed in that subgroup. 33 To date, dual blockade with trastuzumab and pertuzumab plus Cancer chemotherapy should be considered the standard of care for patients with HER2-positive breast cancer who meet criteria for neoadjuvant treatment. In patients who have tumors measuring <2 cm and no lymph node involvement (ie, clinical T1N0 disease), there are no data to recommend neoadjuvant treatment with pertuzumab. [30] [31] [32] [33] [34] Moreover, considering the excellent outcomes of patients with small HER2-positive breast cancers who received adjuvant paclitaxel and trastuzumab (the APT trial), as described below, in most of these patients, adjuvant treatment should be recommended (see Fig. 2 ). In the adjuvant setting, results of the APHINITY were recently reported. 35 That phase 3 trial included approximately 4800 patients with early HER2-positive breast cancer and compared chemotherapy plus trastuzumab and pertuzumab versus chemotherapy plus trastuzumab and placebo. The primary endpoint was invasive-DFS (iDFS) and favored the pertuzumab arm (94.1% vs 93.2%), with a hazard ratio of 0.81(P = .045); patients in that trial who had lymph node-positive and HR-negative breast cancer appeared to derive the greatest benefit from pertuzumab. Although APHINITY was a positive trial, it is important to consider that the addition of pertuzumab was associated with a very small benefit in the overall population, produced some additional toxicity and it is associated with significant financial cost. Therefore, pertuzumab should be reserved only for high-risk patients (with lymph node-positive or highrisk, HR-negative breast cancer). In addition, there are currently no clear guidelines for the use of adjuvant pertuzumab in patients who received neoadjuvant pertuzumab, particularly in those who achieved a pCR. Adjuvant treatment in most of the neoadjuvant studies of pertuzumab consisted of single-agent trastuzumab, [30] [31] [32] and only in the BERENICE study 33 did patients continue to receive adjuvant dual blockade with trastuzumab and pertuzumab. Considering the 5-year analysis of the NeoSphere trial, 34 although it was underpowered, and because a pCR in breast and lymph nodes is an early indicator of long-term outcome in early HER2-positive breast cancer, it may be reasonable to continue adjuvant trastuzumab without pertuzumab in some patients who achieve a pCR. However, data are lacking in this area, and it might be argued that dual blockade with pertuzumab and trastuzumab may have contributed to the outstanding pathologic response rate; thus, it may be these patients who would derive continued benefit. Further studies are needed to gain a better understanding of the utility of adjuvant systemic therapy in patients who achieve a pCR. 35 
Lapatinib
Lapatinib is an oral small-molecule tyrosine kinase inhibitor that reversibly binds and inhibits both HER1 and Cancer HER2. It has demonstrated activity in the metastatic setting when combined with chemotherapy 36 or with trastuzumab as dual blockade without chemotherapy. 37 The activity of lapatinib, trastuzumab, or their combination with or without chemotherapy has been assessed in many neoadjuvant trials (Table 3) . 11, [38] [39] [40] [41] [42] [43] [44] Overall, the trials indicated that lapatinib not only was inferior to trastuzumab in terms of pCR but also was associated with more toxicity. 40, 45 Although dual HER2 blockade with lapatinib and trastuzumab produced a significant improvement in pCR in several of those trials, 38, 40, 42 it did not translate into an impact on event-free survival. 46 Furthermore, in the adjuvant setting, the phase 3 Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial 46 accrued 8381 patients with HER2-positive breast cancer and randomly assigned them to receive 1 year of either trastuzumab alone, lapatinib alone, their sequence, or their combination. That trial demonstrated inferiority of the lapatinib-alone arm compared with trastuzumab or their combination. No significant differences were observed in either DFS or OS between the dual-blockade arm and the trastuzumab-alone arm. Together, these results indicate that, to date, there is no role for lapatinib in the treatment of patients with early stage, HER2-positive breast cancer outside of a clinical trial.
Neratinib
Neratinib is a potent, irreversible, pan-HER tyrosine kinase inhibitor that has demonstrated efficacy in trastuzumab-pretreated, HER2-positive breast cancer. 47 The ExteNET trial 19 is a phase 3, randomized study that evaluated the role of 1 year of extended adjuvant neratinib or placebo in patients with HER2-positive breast cancer who already had completed a year of trastuzumab. That Figure 2 . This is a suggested treatment algorithm for early stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. ACTH indicates anthracycline and cyclophosphamide followed by a taxane and trastuzumab; ER+, estrogen receptor-positive; ET, endocrine therapy; pN, pathologic lymph node status; pT, pathologic tumor classification; TCH, docetaxel plus carboplatin with trastuzumab; TCHP, docetaxel plus carboplatin with trastuzumab plus pertuzumab; TH, weekly paclitaxel and trastuzumab; THP, docetaxel plus carboplatin with trastuzumab; pCR, pathologic complete response.
Cancer trial demonstrated a maintained benefit in iDFS at 5 years (90.2% vs 87.7%; hazard ratio, 0.73; P = .0083) for neratinib-treated patients. However, this benefit was at the expense of increased gastrointestinal toxicity (mainly diarrhea). Prospectively defined subgroup analyses indicated a greater benefit with neratinib in patients who had HR-positive tumors (most of whom received concurrent endocrine therapy), those who had multiple positive lymph nodes, and those who had poorly differentiated or undifferentiated tumors, although the test for interaction was not significant. 19 On the basis of those results, in July 2017, the FDA approved neratinib as extended adjuvant treatment for patients with early stage, HER2-positive breast cancer after adjuvant trastuzumab-based therapy. Of note, in the ExteNET trial, OS has not yet been reported, and it is unclear whether this benefit in iDFS will persist in pertuzumab-pretreated patients. That said, there may be patients with high-risk, HER2-positive breast cancer for whom neratinib is a reasonable option, particularly those who have high-risk HR-positive disease.
Ado-Trastuzumab Emtansine
Ado-trastuzumab emtansine (T-DM1) is an antibody drug conjugate in which a microtubule toxin (emtansine) is linked with trastuzumab. After binding to HER2, the conjugate is internalized, and emtansine is released within the cell, resulting in cell death. In the metastatic setting, T-DM1 has produced impressive results, with significant improvements in both DFS and OS among patients who previously had progressed on trastuzumabbased therapy. 48, 49 T-DM1 is under active clinical investigation in early stage, HER2-positive breast cancer. Results from 2 randomized studies in the neoadjuvant setting already have been reported (Table 4) , 50, 51 including the phase 3 KRISTINE trial. 50 Although these data indicate that T-DM1 may not be as effective as chemotherapy plus trastuzumab and pertuzumab for high-risk patients, it is associated with less toxicity. 50, 51 Two phase 3 trials are ongoing to assess its potential use in the adjuvant setting: the KATHERINE trial (clinicaltrials.gov identifier NCT01772472), which is comparing 1 year of T-DM1 versus trastuzumab in patients who have residual disease after neoadjuvant therapy; and the KAITLIN trial (clinicaltrials.gov identifier NCT01966471), which is evaluating the combination of T-DM1 and pertuzumab versus trastuzumab, pertuzumab, and a taxane after anthracyclines in both arms.
NOVEL APPROACHES TO HER2-POSITIVE, EARLY BREAST CANCER

Potential Role of Less Intense or Nonchemotherapy Regimens
Although trastuzumab-based chemotherapy is associated with excellent outcomes, there may be some patients who could do just as well with less therapy. One potential way to select patients for less therapy would be to consider anatomic size. Retrospective series have demonstrated that even small, lymph node-negative, HER2-positive tumors have a significant risk of recurrence that ranges from approximately 10% to 30%. 52 Patients with tumors measuring <2 cm predominantly were excluded from the large pivotal trials of adjuvant trastuzumab. The APT trial (n = 406; a single-arm, phase 2 trial) was conducted specifically to address treatment for this population of patients with lymph node-negative tumors measuring ≤3 cm. 53 Adjuvant treatment consisted of weekly paclitaxel (80 mg/m 2 ) plus weekly trastuzumab for 12 weeks (TH) followed by single-agent trastuzumab to complete 1 year. The 3-year DFS was 98.7%. In the updated analyses at 7 years, DFS was 93.3%, with a 97.5% recurrence-free interval. 54 Another study that enrolled 493 patients with stage I and II, HER2-positive disease investigated a regimen of docetaxel plus cyclophosphamide and trastuzumab for 4 cycles followed by 1 year of trastuzumab. 55 The study demonstrated that, among lymph node-negative patients (n = 391), the 3-year DFS was approximately 98%, which was similar to the APT study results. Although an all-biologic regimen may have even lower toxicity and should be tested in this setting, the addition of other biologic agents to the TH regimen is unlikely to add substantial benefit for this patient population considering the low event rate reported in the APT trial. Given these results, TH is a reasonable treatment approach for most patients with stage I, HER2-positive breast cancer when trastuzumab-based chemotherapy is recomended. There are also ongoing studies examining whether an even less toxic approach may be efficacious for these patients. The ATEMPT trial (clinicaltrials.gov identifier NCT01853748) is an ongoing, randomized, phase 2 trial of T-DM1 versus trastuzumab in stage I, HER2-positive disease; that study has completed accrual, and the results are anticipated in 2019.
Another approach to de-escalating therapy in select patients may be to use less intense chemotherapy regimens with optimized anti-HER2 therapy or to substitute chemotherapy with effective targeted therapies. The highest pCR rates in HER2-positive disease have been reported with chemotherapy plus dual anti-HER2 therapy, especially in the subset of patients with HER2-positive/ HR-negative tumors. 30, 32 However, highly effective biologic therapy can eradicate HER2-positive tumors in a proportion of patients with a favorable toxicity profile, and chemotherapy may represent an overtreatment in these patients. Dual-HER2 blockade alone with or without endocrine therapy has produced activity in terms of pCRs in a substantial percentage of patients. 30, 32, 43, 44 Similarly, the neoadjuvant, phase 2, open-label NA-PHER trial 56 explored the combination of trastuzumab, pertuzumab, palbociclib, and fulvestrant in patients with HER2-positive, estrogen receptor (ER)-positive breast cancer. That chemotherapy-free regimen induced a significant decrease of Ki-67 expression at 2 weeks and at
Cancer surgery (primary endpoint); in addition, a remarkable 27% of patients achieved a pCR in breast and lymph nodes. That pCR rate compares favorably with the rate observed in similar patients who received paclitaxel and dual-HER2 blockade 30 and highlights the cross-talk that exists between cyclin-dependent kinase (CDK) 4/6 and HER2 signaling in breast cancer. These results, together with the rationale existing in vitro and in vivo of the synergistic effect of combining CDK4/6 inhibition with anti-HER2 therapy, as described below, 57 support continued work on this promising approach.
Finally, another strategy to de-escalate therapy is to select patients based on their pathologic response to neoadjuvant therapy. Patients who achieve a pCR with paclitaxel, pertuzumab, and trastuzumab may not need further adjuvant anthracycline-based chemotherapy based on the association of pCR and survival outcomes. However, we still need to identify robust biomarkers that predict response to HER2-directed therapies to determine which patients can benefit from de-escalation strategies.
Predictive Factors of Response or Resistance to Neoadjuvant Anti-HER2 Therapy
Different clinical behaviors and treatment sensitivities can be identified among patients with HER2-positive breast cancers. In early stage, HER2-positive disease, subgroups of patients with ER-positive and ER-negative disease have different patterns of response and recurrence. [20] [21] [22] [23] [24] [25] [26] 30, 31, 33, [38] [39] [40] [41] [42] [43] [44] However, HER2-positive breast cancer is a clinically and biologically heterogeneous disease that is not fully recapitulated by HR status. All intrinsic molecular subtypes can be identified by gene expression analyses. 11, 44 Molecular intrinsic subtypes play a key role in determining response to anti-HER2 treatment, as reported in several neoadjuvant trials. 11, 44, 58, 59 In those trials, the HER2-enriched subtype has consistently been associated with having the highest rate of pCR. Moreover, the PAMELA trial 44 was the first study to demonstrate prospectively that the HER2-enriched molecular subtype within HER2-positive breast cancer is associated with a pCR after neoadjuvant therapy with only dual HER2-blockade (with or without endocrine therapy) and no chemotherapy.
Several other biologic features have been associated with response heterogeneity to anti-HER2 therapy, including alterations in PI3K signaling pathways, 60, 61 alterations in HER2-receptor 62 or other HER family members, HER2 levels, 63 and tumor-infiltrating lymphocytes. 64, 65 More recently, it has been demonstrated that the cyclin D1-CDK4 pathway can mediate resistance to HER2-targeting drugs in vitro and in vivo. 57 It is noteworthy that targeting resistant tumor cells with CDK4/6 inhibitors resensitizes them to anti-HER2 therapy and delays tumor recurrence in HER2-driven breast cancers in vivo. 57 Yet the clinical relevance of most of these features remains unclear; and, to date, no biomarker of response or resistance to HER2-blockade, other than HER2 overexpression and/or amplification and HR-status, have been validated. 66 
CONCLUSIONS
Trastuzumab with chemotherapy has dramatically improved the OS of patients who have early stage, HER2-positive breast cancer. Although there have been many efforts to improve outcomes even further with the addition of anti-HER2 therapies, the added benefits observed with adjuvant pertuzumab or neratinib are small, and no impact on OS has yet been reported. Balancing risks and benefits is critical when evaluating adjuvant dual blockade with pertuzumab plus trastuzumab or extended HER2 inhibition with neratinib after trastuzumab. Those strategies should be reserved for selected high-risk patients. Conversely, there may be some patients who will do just as well with less therapy. One way to consider de-escalation is to use clinical selection of patients, such as those who have low anatomic burden and those who achieve a pCR to anti-HER2-based neoadjuvant therapy Abbreviations: +, positive; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; TCH, docetaxel plus carboplatin, and trastuzumab; T-DM1, trastuzumab and ado-trastuzumab emtansine; pCR, pathologic complete response; WSG, West-German Study Group; ypN, postneoadjuvant therapy lymph node status; ypT, postneoadjuvant therapy tumor classification.
Cancer and may not need further adjuvant chemotherapy. For patients with stage I, HER2-positive breast cancer, although not all require adjuvant trastuzumab-based chemotherapy (particularly those with pT1aN0 disease), a less intense chemotherapy regimen like TH has been adopted with excellent outcomes. Further research is needed to select patients carefully for all of these strategies without putting at risk those who have an excellent outcome with standard treatment and to ensure that additional benefits are not at the expense of increased toxicity and impaired quality of life. Identifying potential biomarkers of response, potentially using molecular intrinsic subtype, early tumor response, tumor-infiltrating lymphocytes, or lack of PI3K mutation, may help us distinguish patient populations who need more treatment from those who can avoid unnecessary treatments and their associated costs and toxicities.
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